Sulfamides and their use as endothelin receptor antagonists

Details Sulfamides and their use as endothelin receptor antagonists Sulfamides and their use as endothelin receptor antagonists

2006-08-22

2006-08-22

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S255050, C514S269000, C544S123000, C544S296000, C544S319000

Reexamination Certificate

active

07094781

ABSTRACT:
The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

REFERENCES:
patent: 4233294 (1980-11-01), Maurer et al.
patent: 0 526 708 (1993-02-01), None
patent: 0 633 259 (1995-01-01), None
patent: 0 657 548 (1995-06-01), None
patent: 0 743 307 (1996-11-01), None
patent: 0 882 719 (1998-12-01), None
patent: 0 959 072 (1999-11-01), None
patent: WO 96/16963 (1996-06-01), None
patent: WO 96/19459 (1996-06-01), None
patent: WO 00/42035 (2000-07-01), None
patent: WO 01/17976 (2001-03-01), None
patent: WO 01/46156 (2001-06-01), None
patent: WO 01/81335 (2001-11-01), None
patent: WO 01/81338 (2001-11-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Rubanyi et al., Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology, and Pathophysiology, Pharmacological Reviews, vol. 46, No. 3, pp. 325-415, 1994.
Neidhart, W., et al., Discovery of RO 48-5695: A Potent Mixed Endothelin Receptor Antagonist Optimized from Bosantan, Bioorganic & Medical Chemistry Letters, 7(17):2223-2228, 1997.
Gohring, W., et al., Development of a Process to Prepare 2-Cyanopyimidine on Commercial Scale, Chimia, 50:538-543, Nov. 1996.
Nugent, R., et al., Pyrimidine Thioethers: A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP-Resistant HIV, J. Med. Chem., 41:3793-3803.1998.
March, Jerry, Advanced Organic Chemistry, Fourth Edition, p. 499 and references cited therein, 1992.
Kohara, Y., et al., Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres, J. Med. Chem., 39:5228-5235, 1996.
Graf, R., Chem. Ber., 92:509-513, 1959.
Weiss, G., et al., Liebigs Ann. Chem., 729:40-51, 1969.
Kloek, J., et al., An Improved Synthesis of Suffamoyl Chlorides, J. Org. Chem., 41(25):4028-4029, 1976.
Dickinson, R., et al., Thromboxane Modulating Agents. 3. 1H-Imidazol-1-ylalkyl-and -3-Pyridinylalkyl-Substituted 3-[2-(Arylsulfonyl)amino)etthyl]benzenepropanoic Acid Derivatives as Dual Thromboxane Synthase Inhibitor/Thromboxane Receptor Antagonists, J. Med. Chem., 40:3442-3452, 1997.
Cohen, E., et al., Sulfamoyl Chloride, Sulfamides and Sulfmide, J. Am. Chem. Soc., 84:1994-2002, 1962.
Olson, R., et al., Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of Action, J. Med. Chem., 42:1178-1192, 1999.
Crosby, D., et al., n-Butyl 5-Chloro-2-pyrimidoxyacetate-A Plant Growth Regulator Analog, J. Org. Chem., 25:1916-1919, Nov. 1960.
Morgan, E.D., Synthesis of p-Alkylphenylacetic Acid, Tetrahedron, 23:1735-1738, 1967.
Tozer, M., et al., 4-Chlorobenzyl Sulfonamide and Sulfamide Derivatives of Histamine Homologues: The Design of Potent Histamine H3 Receptor Antagonists, Bioorganic & Medicinal Chemistry Letter 9:3103-3108, 1999.
Dewynter, G., et al., Tetrahedron, 49(1):85-76, 1993.
Bennett, J. Claude, et al., Textbook of Medicine, vol. 1, 20th Edition, 1004-1010.
Rubanyi, G.M., et al., Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology and Pathophysiology, Pharm. Reviews, 46(3), 1994.
Arai, H., et al., Cloning and expression of a cDNA encoding an endothelin receptor, Nature, 348:730-732, 1990.
Breu, V., et al., In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of Eta and ETb receptors, FEBS 13244, 334(2):210-214, Nov. 1993.
Neidhart, W., et al., The Discovery of Nonpeptide Endothelin Receptor Antagonists. Progression towards Bosentan, Chimia, 50:519-524, Nov. 1996.
McMillen, M., et al., Endothelins: Polyfunctional Cytokines, J. Amer. College of Surgeons, 180:621-640, 1995.
Ogawa, Y., et al., Molecular Cloning of a Non-Isopeptide-Selective Human Endothelin Receptor, Biochem. Biophy. Research Comm., 178(1):248-255, Jul. 1991.
Ohlstein, E., et al., Endothelin-1 Modulates Vascular Smooth Muscle Structure and Vasomotion: Implications in Cardiovascular Pathology, Drug Development Research, 29:108-128, 1993.
Sakurai, T., et al., Cloning of cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor, Nature, 348:732-735, Dec. 1990.
Sumner, M., et al., Endothelin ETa and ETb receptors mediate vascular smooth muscle contraction, Br. J. Pharmacol., 107:858-860, 1992.
Yanagisawa, M., et al., A novel potent vascoconstrictor peptide produced by vascular endothelial cells, Nature, 332:411-415, Mar. 1988.

Affiliated with

Also associated with

Rating

Sulfamides and their use as endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfamides and their use as endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamides and their use as endothelin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3634418